TechCentralTechCentral
    Facebook Twitter YouTube LinkedIn
    Facebook Twitter LinkedIn YouTube
    TechCentral TechCentral
    NEWSLETTER
    • News

      Broadcom agrees to buy VMware for $61-billion

      26 May 2022

      The cost for South Africa to quit its coal habit: R4-trillion – study

      26 May 2022

      Apple is feeling the smartphone industry chill

      26 May 2022

      Nvidia was to be the next trillion-dollar tech stock – no more

      26 May 2022

      Reunert would consider buying EOH: ‘We’d be foolish not to’

      25 May 2022
    • World

      Musk pledges more equity to fund Twitter deal

      26 May 2022

      Sony looks beyond the console to PC and mobile gaming

      26 May 2022

      Andreessen Horowitz raises world’s largest crypto fund

      26 May 2022

      Central African Republic’s crypto hub plan has World Bank vexed

      25 May 2022

      Big Tech’s latest dive snuffs out hopes the worst is over

      25 May 2022
    • In-depth

      Bernie Fanaroff – the scientist who put African astronomy on the map

      23 May 2022

      Chip giant ASML places big bets on a tiny future

      20 May 2022

      Elon Musk is becoming like Henry Ford – and that’s not a good thing

      17 May 2022

      Stablecoins wend wobbly way into the unknown

      17 May 2022

      The standard model of particle physics may be broken

      11 May 2022
    • Podcasts

      Spectrum auction opens up big growth opportunities – Ruckus Networks

      26 May 2022

      Everything PC S01E03 – ‘The story of Intel – part 1’

      25 May 2022

      The rewarding and lucrative careers to be had in infosec

      23 May 2022

      Dean Broadley on why product design at Yoco is an evolving art

      18 May 2022

      Everything PC S01E02 – ‘AMD: Ryzen from the dead – part 2’

      17 May 2022
    • Opinion

      A proposed solution to crypto’s stablecoin problem

      19 May 2022

      From spectrum to roads, why fixing SA’s problems is an uphill battle

      19 April 2022

      How AI is being deployed in the fight against cybercriminals

      8 April 2022

      Cash is still king … but not for much longer

      31 March 2022

      Icasa on the role of TV white spaces and dynamic spectrum access

      31 March 2022
    • Company Hubs
      • 1-grid
      • Altron Document Solutions
      • Amplitude
      • Atvance Intellect
      • Axiz
      • BOATech
      • CallMiner
      • Digital Generation
      • E4
      • ESET
      • Euphoria Telecom
      • IBM
      • Kyocera Document Solutions
      • Microsoft
      • Nutanix
      • One Trust
      • Pinnacle
      • Skybox Security
      • SkyWire
      • Tarsus on Demand
      • Videri Digital
      • Zendesk
    • Sections
      • Banking
      • Broadcasting and Media
      • Cloud computing
      • Consumer electronics
      • Cryptocurrencies
      • Education and skills
      • Energy
      • Fintech
      • Information security
      • Internet and connectivity
      • Internet of Things
      • Investment
      • IT services
      • Motoring and transport
      • Public sector
      • Science
      • Social media
      • Talent and leadership
      • Telecoms
    • Advertise
    TechCentralTechCentral
    Home»News»South African firm to help make Pfizer/BioNTech Covid vaccine

    South African firm to help make Pfizer/BioNTech Covid vaccine

    News By Agency Staff21 July 2021
    Facebook Twitter LinkedIn WhatsApp Telegram Email

    Pfizer and BioNTech have struck a deal for South Africa’s Biovac Institute to help manufacture around 100 million doses a year of their Covid-19 vaccine for the African Union, the firms said on Wednesday.

    The deal is to “fill and finish” the vaccine, the final stages of manufacturing where the product is processed and put into vials. It does not cover the complicated processes of mRNA drug substance production, which Pfizer and BioNTech will do at their own facilities in Europe.

    The agreement comes as Pfizer and BioNTech try to sway World Trade Organisation members from supporting a waiver on some intellectual property rights for Covid-19 vaccines.

    Weakening IP rules will only discourage the type of unprecedented innovation which brought vaccines forward in record time…

    It will make Biovac — a joint venture between the South African government and private sector partners — one of the few companies in Africa processing and distributing Covid-19 shots, and the first to do so using the mRNA technology.

    South African pharmaceutical company Aspen has a “fill and finish” deal with Johnson & Johnson for its viral vector Covid-19 vaccine.

    African countries have some of the lowest vaccination rates worldwide, and many are dependent on global vaccine sharing scheme Covax, which has struggled to deliver.

    100 million

    Morena Makhoana, CEO at Cape Town-based Biovac, said the aim was to start producing shots “towards the second half of 2022” and then ramp up to maximum output of around 100 million doses a year by early 2023. On-site development and equipment installation would begin immediately, Pfizer and BioNTech said.

    Makhoana said Biovac would modify its plant by expanding next to the filling line and investing in new freezers, as the vaccine needs to be stored at -70°C.

    President Cyril Ramaphosa, who the African Union has named its “champion on Covid-19”, called the agreement a breakthrough in efforts to overcome vaccine inequity. He added it entailed a shared investment of R200-million in the coming six months.

    WTO members have been in talks for months on waiving drug firms’ intellectual property rights for Covid-19 vaccines. Many developing countries including South Africa and India support the waiver, but several wealthy countries remain opposed, saying it would deter research that allowed Covid-19 vaccines to be produced so quickly.

    “Weakening IP rules will only discourage the type of unprecedented innovation which brought vaccines forward in record time and make it harder for companies to collaborate,” Pfizer CEO Albert Bourla said in remarks prepared for a WTO summit later on Wednesday.

    The World Health Organisation last month chose a consortium including Biovac for a “tech transfer hub” in South Africa, part of efforts to give poor and middle-income countries the knowledge and licences to produce Covid-19 vaccines.

    Biovac has partnered with Pfizer since 2015 to manufacture and distribute its Prevnar 13 pneumonia vaccine, although it is still awaiting regulatory approval, Makhoana said. “Having an existing relationship always helps,” he said on his company’s expanded ties with Pfizer.  — Reported by Michael Erman, Wendell Roelf and Alexander Winning, (c) 2021 Reuters

    Albert Bourla BioNTech Biovac Cyril Ramaphosa Morena Makhoana Pfizer top
    Share. Facebook Twitter LinkedIn WhatsApp Telegram Email
    Previous ArticleFour new Icasa councillors sought
    Next Article Naspers invests R34-million in SA insuretech start-up Ctrl

    Related Posts

    Broadcom agrees to buy VMware for $61-billion

    26 May 2022

    The cost for South Africa to quit its coal habit: R4-trillion – study

    26 May 2022

    Apple is feeling the smartphone industry chill

    26 May 2022
    Add A Comment

    Comments are closed.

    Promoted

    BT, MTN Business form strategic alliance in Africa

    26 May 2022

    Think like a start-up: how to build a competitive digital enterprise

    26 May 2022

    Breaking barriers: new payment solution opens up the online market

    26 May 2022
    Opinion

    A proposed solution to crypto’s stablecoin problem

    19 May 2022

    From spectrum to roads, why fixing SA’s problems is an uphill battle

    19 April 2022

    How AI is being deployed in the fight against cybercriminals

    8 April 2022

    Subscribe to Updates

    Get the best South African technology news and analysis delivered to your e-mail inbox every morning.

    © 2009 - 2022 NewsCentral Media

    Type above and press Enter to search. Press Esc to cancel.